ArticleFrontiers in oncology2026
Serum metabolomics modelling reveals stage-associated purine and endocannabinoid metabolic signatures in colorectal cancer progression.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) remains one of the major challenges in contemporary oncology. Despite advances in imaging diagnostics and histopathological assessment, we still lack tools for the early detection of micrometastases and molecular alterations. The purinergic and endocannabinoid systems play an important role in CRC pathogenesis, yet their mutual interactions are not fully understood. Methods: The study involved serum samples from 117 patients undergoing CRC surgical treatment. We performed targeted serum metabolomic profiling of purine metabolites and endocannabinoid-related lipids. Advanced statistical modeling (elastic-net regression and stepwise selection) was applied to link metabolite concentrations with TNM stage and pathological features, such as neuroinvasion and vascular infiltration. Results: AMP was the strongest marker positively correlated with higher TNM stage. On the other hand, 2-AG level showed consistent negative correlation with neuroinvasion and lymphatic nodes metastasis. Xanthine level and N stage correlation was also observed. Conclusions: The results allow us to propose a model in which AMP and 2-AG constitute opposing poles of the metabolic profile in CRC patients An increase in serum AMP was associated with more advanced CRC stage, whereas lower 2-AG levels were associated with invasive features, particularly neuroinvasion. This suggests that altered purine/nucleotide metabolism may be associated with reduced endocannabinoid tone in advanced CRC. However, the proposed interaction between purinergic signalling, COX-2 activity and 2-AG metabolism should be interpreted as a hypothesis-generating model requiring direct tissue-level validation. These findings support further investigation of purine-endocannabinoid crosstalk as a potential biologically relevant pathway in CRC progression, but therapeutic implications require direct tissue-level and functional validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.